Add like
Add dislike
Add to saved papers

Healthcare-associated versus community-associated infective endocarditis in children.

BACKGROUND: Infective endocarditis (IE) in children is continuously changing in regard to underlying conditions, predisposing factors, etiologic agents, clinical manifestations, treatment, and outcome. We describe current characteristics and compare healthcare-associated and community-associated disease.

PATIENTS AND METHODS: All children (<18 years) who were treated at our center between January 1992 through June 2004 and met the Duke criteria for definite or possible IE were included. Demographic, clinical, and laboratory data were collected. Cases were categorized as healthcare- or community-associated.

RESULTS: A total of 50 children with IE were identified (51 events; 0.32/1000 hospitalizations). Twenty children (41%) had an isolated congenital heart disease, 13 (25%) had an underlying chronic disease, 9 (18%) were previously healthy, and 8 (16%) were preterm. Mortality rate was 12% (6/51). Compared with the community-associated cases (21/51, 41%), the healthcare-associated cases (30/51, 59%) showed female preponderance, younger age, 1.7-fold longer hospitalization, 1.6-fold longer time to pathogen eradication, and 3.4-fold higher mortality. The leading causes of healthcare-associated IE were Candida sp (8/30, 27%), coagulase-negative staphylococci (6/30, 20%), and Gram-negative bacilli (5/30, 16%). By contrast, the leading causes of community-associated IE were viridans streptococci (8/21, 38%) and Staphylococcus aureus (4/21, 19%).

CONCLUSIONS: A high proportion of pediatric IE is healthcare-associated that occurs in younger and sicker children. Healthcare-associated IE differs from community-associated IE in the patients' age, causative pathogens, and mortality. These trends and the different etiologies may affect future antibiotic management of this important pediatric infection.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app